# SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. is a public company headquartered in Irvine, CA, United States.

## Company overview

- **Legal name:** SpyGlass Pharma, Inc.
- **Former names in filing history:** SpyGlassPharma, Inc. (2023-07-11 to 2025-06-05); SpyGlass Ophthalmics, Inc. (2019-06-05 to 2021-01-05)
- **Classification:** Public company
- **Industry (SIC):** 3841 — Surgical & Medical Instruments & Apparatus
- **Headquarters:** Irvine, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001778922
- **Website:** spyglasspharma.com (https://spyglasspharma.com/)

## About

SpyGlass Pharma develops sustained drug-delivery systems for chronic eye conditions. Its investigational BIM-IOL system combines drug pads with an intraocular lens designed for use during cataract surgery. On October 1, 2026, SpyGlass completed the acquisition of Advanced Vision Science, its intraocular-lens supplier, from Santen. The transaction brought that lens business into the group; BIM-IOL remains investigational. Its reported principal executive office is in Irvine, CA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included a net loss of USD 39,869,000; cash used in operations of USD 32,701,000. At that year-end, it reported total assets of USD 115,866,000 and cash and cash equivalents of USD 96,358,000.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Net income:** -$39.9M (USD -39,869,000)
- **Total assets:** $115.9M (USD 115,866,000)
- **Cash and equivalents:** $96.4M (USD 96,358,000)
- **Operating cash flow:** -$32.7M (USD -32,701,000)

## Recent SEC filings

- Form 8-K — filed 2026-10-01 — period 2026-10-01 — 8-K
- Form 10-Q — filed 2026-08-06 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-06 — period 2026-08-06 — 8-K
- Form 10-Q — filed 2026-05-14 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-14 — period 2026-05-14 — 8-K
- Form 10-K — filed 2026-03-26 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-03-26 — period 2026-03-26 — 8-K
- Form 8-K — filed 2026-03-09 — period 2026-03-09 — 8-K
- Form 8-K — filed 2026-02-13 — period 2026-02-12 — 8-K
- Form 8-K — filed 2026-02-09 — period 2026-02-05 — 8-K
- Form 424B4 — filed 2026-02-06 — 424B4
- Form S-1 — filed 2026-01-16 — S-1

---

Updated: 2026-10-15T20:59:03.086Z

Canonical page: https://altss.com/profile/spyglass-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology